Glatiramer acetate in multiple sclerosis

Domenico M. Mezzapesa, Marco Rovaris, Massimo Filippi

Research output: Contribution to journalArticlepeer-review


Glatiramer acetate (Copaxone®) is a disease-modifying agent approved by several health authorities worldwide for the treatment of relapsing-remitting multiple sclerosis. Although its primary target is the inflammatory component of the disease, there are emerging pieces of evidence suggesting that glatiramer acetate might also have a neuroprotective effect. In this review, the results of glatiramer acetate clinical trials and other relevant studies as well as the place of glatiramer acetate among other approved disease-modifying treatments for relapsing-remitting multiple sclerosis are discussed critically.

Original languageEnglish
Pages (from-to)451-458
Number of pages8
JournalExpert Review of Neurotherapeutics
Issue number4
Publication statusPublished - Jul 2005


  • Glatiramer acetate
  • Immunomodulation
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Glatiramer acetate in multiple sclerosis'. Together they form a unique fingerprint.

Cite this